Abstract
Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Infectious Disorders - Drug Targets
Title:Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology
Volume: 13 Issue: 1
Author(s): Eda Karadag-Oncel and Mehmet Ceyhan
Affiliation:
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Abstract: Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Export Options
About this article
Cite this article as:
Karadag-Oncel Eda and Ceyhan Mehmet, Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990004
DOI https://dx.doi.org/10.2174/18715265112129990004 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics West Nile Virus NS2B/NS3 Protease As An Antiviral Target
Current Medicinal Chemistry Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets In silico Designing and Screening of Lead Compounds to NS5-Methyltransferase of Dengue Viruses
Medicinal Chemistry Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Nano-formulations for Diagnostics and Therapeutics of Foot-and-Mouth Disease in Animals
Nanoscience & Nanotechnology-Asia Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Neuroprotective Therapy for HIV Dementia
Current HIV Research MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Glycine Rich P-loop Motif in Deoxyuridine Pyrophosphatase
Current Protein & Peptide Science Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) HIV-1: The Confounding Variables of Virus Neutralization
Current Drug Targets - Infectious Disorders Editorial (Thematic Issue: The Monocyte/Macrophage in the Pathogenesis of AIDS: The Next Frontier for Therapeutic Intervention in the CNS and Beyond: Part II)
Current HIV Research